[{"orgOrder":0,"company":"Novaremed","sponsor":"GEM Global Yield","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"NRD135S.E1","moa":"Lyn kinase","graph1":"Neurology","graph2":"Phase II","graph3":"Novaremed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Novaremed \/ GEM Global Yield","highestDevelopmentStatusID":"8","companyTruncated":"Novaremed \/ GEM Global Yield"},{"orgOrder":0,"company":"Novaremed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"NRD135S.E1","moa":"Lyn kinase","graph1":"Neurology","graph2":"Phase II","graph3":"Novaremed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Novaremed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novaremed \/ Inapplicable"},{"orgOrder":0,"company":"Novaremed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"NRD135S.E1","moa":"Lyn kinase","graph1":"Neurology","graph2":"Phase II","graph3":"Novaremed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Novaremed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novaremed \/ Inapplicable"},{"orgOrder":0,"company":"Novaremed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"NRD135S.E1","moa":"Lyn kinase","graph1":"Neurology","graph2":"Phase II","graph3":"Novaremed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Novaremed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novaremed \/ Inapplicable"},{"orgOrder":0,"company":"Novaremed","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NRD135S.E1","moa":"Lyn kinase","graph1":"Neurology","graph2":"Phase II","graph3":"Novaremed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Novaremed \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Novaremed \/ National Institutes of Health"},{"orgOrder":0,"company":"Novaremed","sponsor":"NeuroFront Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"NRD135S.E1","moa":"Lyn kinase","graph1":"Neurology","graph2":"Phase II","graph3":"Novaremed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Novaremed \/ NeuroFront Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Novaremed \/ NeuroFront Therapeutics"},{"orgOrder":0,"company":"Novaremed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"NRD135s.E1","moa":"Lyn kinase","graph1":"Neurology","graph2":"Phase II","graph3":"Novaremed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Novaremed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novaremed \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Novaremed

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          IMCAS Asia
                          Not Confirmed
                          IMCAS Asia
                          Not Confirmed

                          Details : NRD.E1 (or NRD135S.E1), an orally active small molecule with a novel mechanism of action, is being developed to treat chronic pain associated with diabetic peripheral neuropathy.

                          Product Name : NRD.E1

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 06, 2025

                          Lead Product(s) : NRD135s.E1

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          IMCAS Asia
                          Not Confirmed
                          IMCAS Asia
                          Not Confirmed

                          Details : NeuroFront receives an exclusive option for an exclusive license to develop, commercialize and manufacture NRD.E1, Novaremed’s first-in-class, non-opioid investigational drug for the treatment of chronic neuropathic pain in Greater China and Singapore.

                          Product Name : NRD.E1

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          July 21, 2022

                          Lead Product(s) : NRD135S.E1

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : NeuroFront Therapeutics

                          Deal Size : $130.0 million

                          Deal Type : Licensing Agreement

                          blank

                          03

                          IMCAS Asia
                          Not Confirmed
                          IMCAS Asia
                          Not Confirmed

                          Details : In summary, data from these 4 studies now published demonstrate the potential of NRD.E1 (NRD135S.E1) as an innovative non-opioid treatment option for patients with painful diabetic peripheral neuropathy (PDPN).

                          Product Name : NRD.E1

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          June 23, 2022

                          Lead Product(s) : NRD135S.E1

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : National Institutes of Health

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          IMCAS Asia
                          Not Confirmed
                          IMCAS Asia
                          Not Confirmed

                          Details : The primary efficacy endpoint aims to demonstrate superiority of NRD.E1 compared to placebo in relieving PDPN. The secondary objectives of the study are to evaluate the pharmacokinetics, safety, and tolerability of NRD.E1, and assess several additional e...

                          Product Name : NRD.E1

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          December 21, 2021

                          Lead Product(s) : NRD135S.E1

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          IMCAS Asia
                          Not Confirmed
                          IMCAS Asia
                          Not Confirmed

                          Details : The proceeds from this financing will be used to progress the clinical development of Novaremed’s lead product, NRD135S.E1, an investigational non-opioid small molecule drug for the treatment of painful diabetic peripheral neuropathy (PDPN).

                          Product Name : NRD.E1

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          January 28, 2021

                          Lead Product(s) : NRD135S.E1

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : GEM Global Yield

                          Deal Size : $50.0 million

                          Deal Type : Agreement

                          blank

                          06

                          IMCAS Asia
                          Not Confirmed
                          IMCAS Asia
                          Not Confirmed

                          Details : In a Phase 2a Proof of Concept study, NRD135S.E1 showed clinically relevant reduction in patient-reported pain and an excellent safety and tolerability profile. Novaremed Ltd is currently preparing to conduct a Phase 2b study in PDPN patients in USA.

                          Product Name : NRD.E1

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          December 18, 2020

                          Lead Product(s) : NRD135S.E1

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          IMCAS Asia
                          Not Confirmed
                          IMCAS Asia
                          Not Confirmed

                          Details : The Phase 2 study, designed as a randomized, double-blind, placebo-controlled study, will enroll patients with neuropathic pain caused by Diabetes Mellitus. Eligible patients will be randomized to receive oral doses of either NRD135S.E1 or placebo once d...

                          Product Name : NRD.E1

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 25, 2020

                          Lead Product(s) : NRD135S.E1

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank